- Specialization
- Robotics
- Business
- Data Provision
- Market
- Manufacturing
- Ecosystem
- Not classified
- Customers
Enterprisesand 1 more customers valuesLess
- Researchers
More details
- Organization type
- Commercial Company
- Ecosystem
- Not classified
- Business
- Data Provision
- Specialization
- Robotics
- Market
- Manufacturing
- Customers
- Enterprises, Researchers
- Delivery models
- Professional Services
- Revenue models
- Product Sales, Services Fees
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
Asimov builds end-to-end infrastructure for collecting, annotating, and delivering diverse real-world human movement data to humanoid-robot developers and leading robotics laboratories. Its differentiator is a vertically integrated network spanning households and businesses, proprietary collection hardware, annotation tools, and data operations that produce broader and cheaper training datasets than factory-only approaches.
Market
Asimov competes in the embodied-AI and physical-robotics data-infrastructure market, supplying the real-world human-motion data needed to train humanoid and other robots. It differentiates from conventional teleoperation and factory datasets by collecting diverse activity from ordinary people in households, workplaces, and businesses, then delivering a vertically integrated pipeline from hardware distribution through QA and annotated, training-ready datasets. Sensei, Mecka AI, Scale AI, Foxglove, and Segments.ai overlap with parts of this market through human-demonstration collection, physical-AI data infrastructure, robotics annotation, or multimodal dataset management.
Asimov targets robotics companies and frontier or large robotics labs developing humanoid and other embodied-AI systems, particularly teams that need large-scale human-motion data and training datasets. Its likely buyers are robotics, machine-learning, and autonomy leaders responsible for collecting and preparing data for robot foundation models.
At a Glance
Problem
Humanoid and other embodied-AI robots face a fundamental data bottleneck: they need to learn how people move through messy, varied physical environments, but conventional factory datasets capture repetitive tasks in standardized settings. Asimov targets the resulting gap by collecting everyday human activity in homes, kitchens, offices, hotels, restaurants, warehouses, and other workplaces. The core use case is supplying the diverse movement and interaction data needed to train robots that must operate beyond controlled factories.
The pain is both technical and economic. Robotics companies need large volumes of high-quality, annotated demonstrations, while collecting them manually or building dedicated environments is expensive and lacks environmental diversity. Asimov also addresses the supply-side economics by turning ordinary work and household activity into paid data collection; participating businesses can have worker salaries covered while their operations continue normally.
Product / Service
Asimov operates a managed, vertically integrated data-collection service for robotics teams. Individuals apply with their location, phone model, availability, and access to relevant tasks, then use a lightweight phone head mount and an app to record assigned activities. Businesses can have employees wear recording equipment while doing their normal jobs. Asimov handles hardware distribution, collector training, quality assurance, annotation, and post-processing, delivering clean datasets ready for model training.
The model creates a two-sided benefit: collectors are paid for approved recording time, while robotics customers receive real-world, multimodal data from many people and environments without having to build their own collection network. For larger business partnerships, Asimov offers salary coverage and revenue sharing from the resulting datasets, while its privacy guidance and non-disruptive workflow are designed to reduce operational and data-governance friction.
Market
Asimov competes in the emerging embodied-AI and robotics-training-data market, with a particular focus on humanoid robots. Its differentiation is a broad, real-world supply chain rather than a factory-only or lab-only dataset: the company combines households and businesses, proprietary collection hardware, and annotation tooling into an end-to-end pipeline. A close publicly identified competitor is YC-backed Sensei, which likewise provides outsourced robotics training-data collection using hardware for human demonstrations; larger data-services companies such as Scale AI are adjacent alternatives, although the available evidence does not establish an exhaustive competitor set.
The company is early but shows meaningful commercial traction. It is an active Winter 2026 Y Combinator company, says it is collecting across three continents and is trusted by frontier robotics teams, and reports a network of thousands of households and businesses, tens of thousands of hours already shipped to frontier robotics teams, and customers among the largest robotics labs. Public materials reviewed do not disclose revenue, so Asimov should not be definitively labeled pre-revenue; the best-supported description is an early-stage company with active customer delivery and expanding data-collection operations.
Founders & Leadership
Funding History
Y Combinator
Recent News
Asimov joined the Genesis Mission and will help build protein production and characterization capabilities at Boston University's AI-programmable cloud laboratory, one of 20 mission nodes.
Asimov launched Chrysalis Transposase, engineered from the genomes of multiple butterfly species. The tool is described as enabling fast cell recovery and stable expression over 60 cellular generations.
Asimov launched RNA Edge, a lab-in-the-loop platform designed to use AI to optimize RNA therapeutic candidates.
Asimov announced a cell-line development partnership with Score Pharma to advance biosuperior antibody therapeutics.
Asimov launched a stable AAV cell-line development service reporting titers up to 6E15 vg/L before purification in under 20 weeks.
Asimov announced a cell-line development partnership with Ottimo Pharma and delivered a high-titer, stable CHO cell line ahead of schedule to support an IND submission planned for late 2025.
Active Roles
2Business Model
Asimov sells real-world human movement datasets and related data-collection and teleoperation services to robotics companies and laboratories. It partners with businesses such as restaurants, warehouses, and cleaning companies, often covering worker salaries and sharing revenue from data sales; it also operates a cleaning service that supplies collection labor.